• 1
    Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1.
  • 2
    Rosenberg SA. Validity of the Ann Arbor staging classification for non-Hodgkin's lymphoma. Cancer Treat Rep 1977; 61: 1023-7.
  • 3
    Shipp MA, Harrington DP, Klatt MM, Jochelson MS, Pinkus GS, Marshall JL, et al. Identification of major prognostic subgroups of patients with large cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104: 757-65.
  • 4
    Jagannath S, Velasquez WS, Tucker SL, Fuller LM, Mc Laughlin PW, Mannig JT, et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 1986; 4: 859-65.
  • 5
    Danieu L, Wong G, Koziner B, Clarkson B. Predictive model for prognostic model in advanced diffuse histiocytic lymphoma. Cancer Res 1986; 46: 5372-9.
  • 6
    Coiffier B, Lepage E. Prognosis of aggressive lymphoma: a study of five prognostic models with patients included in the LNH-84 regimen. Blood 1989; 74: 558-64.
  • 7
    Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A, et al. Prognostic factors in aggressive malignant lymphoma: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991; 9: 211-9.
  • 8
    The international non-Hodgkin's lymphoma prognostic factors project: a predictive model for aggressive lymphoma. N Engl J Med 1993; 329: 987-94.
  • 9
    Cox DR. Regression model and life tables. J R Stat Soc B 1972; 34: 187-220.
  • 10
    Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N, et al. LNH-84 regimen a multicentric study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989; 7: 1018-26.
  • 11
    Tilly H, Coiffier B, Brice P. Localized low-bulk aggressive lymphomas treated with chemotherapy alone in the LNH-87 protocol: a GELA study [Abstract P111]. Fifth International Conference on Malignant Lymphoma, Lugano, Switzerland, 1993: 98.
  • 12
    Bosly A, Lepage E, Coiffier B, Dupriez B, Herbrecht R, Fillet G, et al. Alternating does not improve results in poor prognosis aggressive lymphoma. LNH-87 protocol group 3: a GELA study [Abstract 530]. Thirty-fifth meeting of the American Society of Hematology, St. Louis, Missouri, 1993; 82:136a.
  • 13
    Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly A, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission. J Clin Oncol 1994; 12: 2543-51.
  • 14
    Coiffier B. Fourteen years of high-dose CHOP (ACVBP regimen): preliminary conclusions about the treatment of aggressive lymphoma patients. Ann Oncol 1995; 6: 211-7.
  • 15
    Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
  • 16
    Prentice RL, Kalbfleisch JD. Hazard rate model with covariates. Biometrics 1979; 35: 25-39.
  • 17
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
  • 18
    Anderson JA, Senthilselvan A. A two step regression model for hazard functions. Appl Stat 1982; 31: 44-51.
  • 19
    Gore SM, Pocock SJ, Keer GR. Regression model and nonproportional hazards in the analysis of breast cancer survival. Appl Stat 1984; 33: 176-95.
  • 20
    Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has high-risk disease. Blood 1994; 83: 1165-73.
  • 21
    Harrel FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
  • 22
    Grambsch P, Therneau T. Proportional hazard tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-26.
  • 23
    Patte C, Michon J, Frappaz D, Leverger G, Rubie H, Soussain C, et al. Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults. Baillieres Clin Haematol 1994; 7: 339-48.
  • 24
    Hiddemann W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, et al. Lymphoma classification: the gap between biology and clinical management is closing. Blood 1996; 88: 4085-9.
  • 25
    Gisselbrecht C, Gaulard Ph, Lepage E, Coiffier B, Briere J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphoma [Abstract 1159]. Thirty-eighth meeting of the American Society of Hematology, Orlando, Florida, 1996;88:293a.
  • 26
    Coiffier B, Anderson J, Armitage J, Berger F, Cavalli F, Chan W, et al. Clinical prognostic factors are stronger predictors of outcome in non-Hodgkin's lymphoma than pathologic subtype [Abstract 1160]. Thirty-eighth meeting of the American Society of Hematology, Orlando, Florida, 1996; 88:293a.
  • 27
    Hermine O, Haioun C, Lepage E, D'Agay MF, Briere J, Lavignac C, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996; 87: 265-72.
  • 28
    Swan F, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, Mclaughlin P, et al. A new serologic staging system for large-cell lymphomas based on initial β2-microglobulin and lactate deshydrogenase levels. J Clin Oncol 1989; 7: 1518-24.
  • 29
    Roggero E, Zucca E, Bertoni F, Bernier J, Cavalli F. Comparison of prognostic models for diffuse large B cell lymphoma: can β2-microglobulin improve upon the International Prognostic Index? [Abstract 70] Thirty-third meeting of the American Society of Clinical Oncology, Denver, 1997;16:20a.
  • 30
    Philip T, Guglielmi C, Hagenbeek A, Somer R, Van Der Lelie H, Bron D, et al. Autologous bone-marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
  • 31
    Philip T, Gomez F, Bosly A, Biron P, Blay JY, Coiffier B, et al. Salvage treatment for chemotherapy resistant diffuse non-Hodgkin's lymphoma: review of the 215 patients of the PARMA study and rationale for a second prospective study [Abstract 1278]. Thirty-second meeting of the American Society of Clinical Oncology, Seattle, 1996; 15:417a.